Evidence & regulatory context
- Mechanism
- Gene therapy vector; no ChEMBL entity exists, so ChEMBL was not queried. ClinicalTrials.gov searched for 'Nogo-B OR anti-Nogo': 1 hit, NCT01435993 GSK1223249 (ozanezumab) in relapsing multiple sclerosis. DELIBERATE NON-MATCH, REJECTED rather than recorded as a false positive: ozanezumab is a NEUTRALISING antibody against Nogo-A, i.e. both a different isoform and the pharmacological OPPOSITE of adenoviral Nogo-B OVEREXPRESSION. No human trial delivers Nogo-B by viral vector, and no fluorescently tagged construct has ever entered human study. trials left empty and to_trial false by decision, not by omission.
- Target
- Not recorded
- Injury models
- Endotoxin/LPS
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseEndotoxin/LPSC57BL/6Malen = n = 8 per group for survival; n = 5 per group for bronchoal…Intratracheal instillation7 days before lipopolysaccharide challenge
Model: Acute lung injury induced by intratracheal instillation of lipopolysaccharide (Escherichia coli O111:B4), 15 mg/kg for lung injury and inflammation assessment at 12 hours and a lethal dose of 25 mg/kg for survival experiments
Pulmonary Nogo-B fell significantly from 6 hours after lipopolysaccharide, with 4.8-fold down-regulation at 12 hours. Ad-Nogo-B prolonged survival after lethal lipopolysaccharide (28.7 plus or minus 10.78 versus 16.9 plus or minus 4.85 hours, n = 8, p<0.05), lowered the lung injury score (3.2 plus…
Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.
